GammaTile Therapy  |  STaRT


Right Treatment. Right Time. Right Place.

GammaTile Therapy is a surgically targeted radiation therapy 

(STaRT) that provides immediate, dose-intense treatment at completion of resection. By getting a head STaRT on fighting the tumor, resection plus GammaTile Therapy extends local

recurrence-free survival with minimal complications, reduced patient burden, and assured compliance. [1]

Proven Efficacy & Safety

Extends local recurrence-free survival vs previous standard of care treatment [1]

  • Significantly improves outcomes by approximately 2X considering all tumor types in the study

  • Median time to same-site recurrence was 19.9 months, a 9.7–month improvement across all tumor types [1]




Median local control (LC) after GammaTile Therapy vs prior treatment was 12.0 vs 9.5 months for high-grade glioma (HGG) patients (HR 0.6, p = .13) and 48.8 vs 23.3 months (HR 0.24, p = .01) for meningioma patients. For the metastasis patients, the median LC has not been reached vs 5.1 months with prior treatment (HR .07, p = 0.02).[1]  The median overall survival 

(OS) was 12.0 months for HGG patients, 12.0 months for the brain metastasis patients, and 49.2 months for the meningioma patients.[1]



How It Works. An Eloquent Solution.

GammaTile Therapy targets tumor cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications.[1]


Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment. 

Enhanced Local Control and Optimized Efficacy

  • 50% of the therapeutic dose is delivered within the first 
    10 days after surgery, which helps prevent residual tumor cells from replicating.[9]

  • 88% of the therapeutic dose is delivered within 30 days 
    with more than 95% of dose delivered by 6 weeks.[9]

  • A favorable depth-dose profile optimizes local
    tumor control.

Bioresorbable, conformable collagen tile preserves healthy tissue 
  • Provides a structural offset of the radiation source from normal brain tissue

  • Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles

  • Minimizes local hot and cold spots

  • Facilitates rapid, accurate placement to deliver a predictable radiation dose



Excellent Safety Profile: Comparable to or Better Than Currently Available Treatments[1, 4-8]
Therapy Comparison: IMRT vs GammaTile Therapy [1,11]

GammaTile Therapy is a safe and effective, surgically targeted radiation therapy (STaRT) for patients with recurrent brain tumors. [1]

  • Extends local recurrence-free survival with minimal complications [1]

  • Reduces patient burden and preserves quality of life [1]

  • Facilitates favorable reimbursement (CMS craniotomy code ICD-10 MS-DRG 023)


Clinical Efficacy, Immediacy, and Efficiency 

  • Enables immediate treatment at resection with no additional hospital stay 

  • Integrates into the surgical workflow for procedural ease and speed

  • Takes approximately 6 minutes to complete tile placement

  • Simplifies care with 100% "built-in" compliance and no special inpatient precautions or contraindications with systemic therapies


  1. Data on file, GT Medical Technologies, Inc.

  2. Shi W, Bryan MS, Gilbert MR, et al. Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiation Oncol Biol Phys. 2018;100(1):38-44. 

  3. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Euro J Cancer. 2012;48:2192-2202. 

  4. Lin AJ, Hui C, Dahiya S, et al. Radiologic response and disease control of recurrent intracranial meningiomas treated with reirradiation. Int J Radiation Oncol Biol Phys. 2018;102(1):194-203. 

  5. Scossianti S, Franncolini G, Carta G, et al. Re-irradiation as salvage in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions. Crit Rev Oncology. 2018;126:89-91.

  6. Combs SE, Debus J, Schulz-Ertner D. Radiotheraputic alternatives for previously irradiated recurrent gliomas. BMC Cancer. 2007;7:167. 

  7. Wernicke AG, Smith AW, Taube S, et al. Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease. J Neurosurg. 2017;126(4):1212-1219. 

  8.  Magill ST, Lau D, Raleigh DR, Sneed PK, Fogh SE, McDermott MW. Surgical resection and interstitial iodine-125 brachytherapy for high-grade meningiomas: a 25-year series. Neurosurgery. 2017;80(3):409-416. 

  9. Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
    Int J Radiat Oncol Biol Phys. 2003;55(2):378-385. 

  10. Chiu-Tsao ST, Napoli JJ, Davis SD, et al. Dosimetry for 131Cs and 125I seeds in solid water phantom using radiochromic EBT film. Appl Radiat Isot. 2014;92:102-114. 

  11. Pinnaduwage DS, Youssef EF, Sorensen S, Srivastava S, Yan X, Brachman D. Dosimetric impact of radioisotope type on permanent brain seed implants. Paper presented at: American Association of Physicists in Medicine 2017 Annual Meeting; July 30-August 3, 2017; Denver, CO.